Ocular Management Support

The eye care professional is an integral part of the BLENREP journey

The oncologist and eye care professional partner to create one cohesive treatment plan.

  • Eye exams are required with BLENREP1

  • Find an eye care professional near you

 

 

 

BLENREP Eye Drop Supportive Care Program

  • Patients can receive complimentary shipments of eye drops throughout therapy

  • 60 vials of preservative-free lubricant eye drops mailed every 60 days

SOUND FX: 2 heartbeats
ANIMATION: GSK Oncology On Demand for US HCPs


VO: INDICATION
BLENREP (belantamab mafodotin-blmf) is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.


This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.


IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

BLENREP caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms such as blurred vision and dry eyes.


Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms. Withhold BLENREP until improvement and resume, or permanently discontinue, based on severity.


Because of the risk of ocular toxicity, BLENREP is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BLENREP REMS.


Please see IMPORTANT SAFETY INFORMATION and full Prescribing Information, including BOXED WARNING.
TEXT ON SCREEN: BLENREP
belantamab
mafodotin-blmf
for injection 100 mg


INDICATION

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.


This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).


IMPORTANT SAFETY INFORMATION

  1. WARNING: OCULAR TOXICITY
  2. BLENREP caused changes in the corneal epithelium resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms such as blurred vision and dry eyes.
  3. Conduct ophthalmic exams at baseline, prior to each dose, and promptly for worsening symptoms. Withhold BLENREP until improvement and resume, or permanently discontinue, based on severity.
  4. Because of the risk of ocular toxicity, BLENREP is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the BLENREP REMS.

Please see IMPORTANT SAFETY INFORMATION and full Prescribing Information, including BOXED WARNING.


VO: Have you told your patients about BLENREP’s Eye Drop Supportive Care Program?
TEXT ON SCREEN: EYE DROP SUPPORTIVE CARE PROGRAM
Please see Important Safety Information and full Prescribing Information, including BOXED WARNING.


VO: It’s a program that provides free eye drops to patients throughout therapy.
TEXT ON SCREEN: EYE DROPS
60 vials of eye drops every 60 days


VO: Patients will need an ophthalmic exam at baseline, prior to each dose, and promptly for worsening symptoms.
TEXT ON SCREEN: EYE DROPS
Patients will need an ophthalmic exam at baseline, prior to each dose, and promptly for worsening symptoms.


VO: During treatment with BLENREP
TEXT ON SCREEN: Please see Important Safety Information and full Prescribing Information, including BOXED WARNING.


VO: it’s important for patients to apply preservative-free lubricant eye drops at least four times a day
TEXT ON SCREEN: FOUR TIMES PER DAY
Starting with the 1st infusion and continuing until the end of treatment


VO: starting with the 1st infusion and continuing until the end of treatment.
TEXT ON SCREEN: Starting with the 1st infusion and continuing until the end of treatment


VO: The Eye Drop Supportive Care Program can help them do just that.
TEXT ON SCREEN: EYE DROP SUPPORTIVE CARE PROGRAM


VO: Help patients enroll in 3 easy steps:
TEXT ON SCREEN: HELP PATIENTS ENROLL IN 3 EASY STEPS


VO: Print the Eye Drop Supportive Care Program enrollment form
TEXT ON SCREEN: STEP 1
PRINT
View Enrollment Form


VO: from BLENREPHCP.com.
TEXT ON SCREEN: Image of the front of the BLENREP Eye Drop Supportive Care Program form is displayed. The following text matches the text on the front of this form. BLENREP Eye Drop Supportive Care Program


BLENREP
belantamab
mafodotin-blmf
for injection 100 mg


This form must be completed, signed, and submitted before you can receive preservative-free lubricant eye drops. Print and submit the completed form by fax at 1-888-635-1044.

Patient Information
Fields marked * are REQUIRED
First Name*:
Middle Initial:
Last Name*:
Date of Birth (MM/DD/YYYY)*:
Phone Number*:
Email Address:
Address*:
City*:
State*:
ZIP Code:
Shipping address is same as mailing address (above).
Preferred shipping address entered below.
Preferred Shipping Address:
City:
State:
ZIP Code:


Patient Authorization to Use Health Information

By signing this form, I agree to allow my doctors, doctors’ offices, hospitals, infusion
sites, specialty distributor(s), and authorized staff supporting these entities (collectively
“Healthcare Providers”), to use and disclose my health information to GSK and its agents,
authorized representatives, and contractors (collectively “GSK”) so that GSK can use and
disclose my health information for purposes of providing me with preservative-free lubricant
eye drops. The following activities are included:

  1. Utilizing my REMS information such as REMS ID, REMS Enrollment Status, REMS Enrollment Form, Patient Status Forms, Eye Care Professional Consult Forms, and the REMS Checklist completed by my Healthcare Providers.
  2. Communicating with my Healthcare Providers about my BLENREP prescription and medical condition.
  3. Disclosing my information to third parties if required by law.

Access to this form at www.blenrephcp.com Continued on reverse.


Please see Important Safety Information and full Prescribing Information, including BOXED WARNING.


VO: Complete the form with your patient.
TEXT ON SCREEN: STEP 2
*Remember to give your patient a copy of the form for their records!


Animation showing the front of the BLENREP Eye Drop Supportive Care Program form being completed is shown.


TEXT ON SCREEN: STEP 2 *Remember to give your patient a copy of the form for their records!


Image of the back of the BLENREP Eye Drop Supportive Care Program form is displayed. The following text matches the text on the front of this form. Animation showing the back of the BLENREP Eye Drop Supportive Care Program form being completed is shown.


Patient Authorization to Use Health Information (cont’d)


By signing this authorization, I acknowledge my understanding that:

  • My Healthcare Providers will not and may not condition my treatment, payment for treatment, or eligibility for or enrollment in benefits on whether I sign this patient authorization.
  • Once information about me is released to GSK based on this authorization, federal privacy laws may no longer protect my information and may not prevent GSK from further disclosing my information. However, I understand that GSK has agreed to use or disclose information received only for the purposes described in this authorization or as required by law.
  • This authorization will remain in effect for two (2) years after I sign it (unless a shorter period is required by state law) or for as long as I participate in the eye drop program, whichever is longer.
  • I have the right to revoke this authorization at any time by mailing a signed, written statement of my revocation to United BioSource LLC, BLENREP Eye Drop Supportive Care Program, 200 Pinecrest Plaza Morgantown, WV 26505 US, but such a revocation would end my eligibility to participate in the eye drop program. (The revocation process may also be initiated by calling the Coordinating Center at 1-855-209-9188). Revoking this authorization will prohibit further disclosures by my Healthcare Providers based on this authorization after the date a written revocation is received but will not apply to the extent that they have already taken action in reliance on this authorization. After this authorization is revoked, I understand that information provided to GSK prior to the revocation may be disclosed within GSK to maintain records of my participation.

The patient, or the patient’s legal guardian, MUST sign this form in order for the patient to receive preservative-free lubricant eye drops. If a legal guardian signs for the patient, please indicate relationship to the patient.


Patient Signature and Acknowledgment
By signing this form, I agree that GSK can utilize the health information described above,
including my REMS information, to provide me free preservative-free lubricant eye drops.
Patient / Legal Guardian Signature
PRINT NAME
Date
MONTH/DAY/YEAR


Trademarks are owned by or licensed to the GSK group of companies.
©2020 GSK or licensor.
BLMLTR200018 October 2020
Produced in USA. 0002-0009-50


BLENREP
belantamab
mafodotin-blmf
for injection 100 mg


VO: Fax the form
TEXT ON SCREEN: STEP 3


VO: to 1-888-635-1044.
TEXT ON SCREEN: FAX TO:
1-888-635-1044


VO: Once the patient is enrolled, the patient is expected to receive the shipment within 4 business days.
TEXT ON SCREEN: MON 1
TUE 2
WED 3
THU 4
EYE DROPS


VO: After that, your patient will continue to receive an eye drop shipment in the mail
TEXT ON SCREEN: EYE DROPS
These eye drops are intended to serve as a sample. If your patient runs out during treatment, then your patient will need to purchase additional preservative-free eye drops. There are instructions about purchasing the correct over-the-counter drops in the BLENREP REMS Patient Guide.


VO: every 60 days throughout therapy. TEXT ON SCREEN: EVERY 60 DAYS These eye drops are intended to serve as a sample. If your patient runs out during treatment, then your patient will need to purchase additional preservative-free eye drops. There are instructions about purchasing the correct over-the-counter drops in the BLENREP REMS Patient Guide.


VO: Tell your patients about an additional supportive resource during treatment with BLENREP.
TEXT ON SCREEN: Enroll your patients at


VO: Download the enrollment form and get your patient started today at www.BLENREPHCP.com TEXT ON SCREEN: Enroll your patients at BLENREPHCP.com


VO: WARNINGS AND PRECAUTIONS.
Ocular Toxicity: Ocular adverse reactions occurred in 77% of the 218 patients in the pooled safety population. Ocular adverse reactions included keratopathy (76%), changes in visual acuity (55%), blurred vision (27%), and dry eye (19%). Among patients with keratopathy (n = 165), 49% had ocular symptoms, 65% had clinically relevant visual acuity changes (decline of 2 or more lines on Snellen Visual Acuity in any eye), and 34% had both ocular symptoms and visual acuity changes.


Keratopathy: Keratopathy was reported as Grade 1 in 7% of patients, Grade 2 in 22%, Grade 3 in 45%, and Grade 4 in 0.5% per the KVA scale. Cases of corneal ulcer (ulcerative and infective keratitis) have been reported. Most keratopathy events developed within the first 2 treatment cycles (cumulative incidence of 65% by Cycle 2). Of the patients with Grade 2 to 4 keratopathy (n = 149), 39% recovered to Grade 1 or lower after median follow-up of 6.2 months. Of the 61% who had ongoing keratopathy, 28% were still on treatment, 9% were in follow-up, and in 24% the follow-up ended due to death, study withdrawal, or lost to follow-up. For patients in whom events resolved, the median time to resolution was 2 months (range: 11 days to 8.3 months).


Visual Acuity Changes: A clinically significant decrease in visual acuity of worse than 20/40 in the better-seeing eye was observed in 19% of the 218 patients and of 20/200 or worse in the better-seeing eye in 1.4%. Of the patients with decreased visual acuity of worse than 20/40, 88% resolved and the median time to resolution was 22 days (range: 7 days to 4.2 months). Of the patients with decreased visual acuity of 20/200 or worse, all resolved and the median duration was 22 days (range: 15 to 22 days).


Monitoring and Patient Instruction: Conduct ophthalmic examinations (visual acuity and slit lamp) at baseline, prior to each dose, and promptly for worsening symptoms. Perform baseline examinations within 3 weeks prior to the first dose. Perform each follow-up examination at least 1 week after the previous dose and within 2 weeks prior to the next dose. Withhold BLENREP until improvement and resume at same or reduced dose, or consider permanently discontinuing based on severity. Advise patients to use preservative-free lubricant eye drops at least 4 times a day starting with the first infusion and continuing until end of treatment. Avoid use of contact lenses unless directed by an ophthalmologist. Changes in visual acuity may be associated with difficulty for driving and reading. Advise patients to use caution when driving or operating machinery. BLENREP is only available through a restricted program under a REMS.


Thrombocytopenia: Thrombocytopenia occurred in 69% of 218 patients in the pooled safety population, including Grade 2 in 13%, Grade 3 in 10%, and Grade 4 in 17%. The median time to onset of the first thrombocytopenic event was 26.5 days. Thrombocytopenia resulted in dose reduction, dose interruption, or discontinuation in 9%, 2.8%, and 0.5% of patients, respectively. Grade 3 to 4 bleeding events occurred in 6% of patients, including Grade 4 in 1 patient. Fatal adverse reactions included cerebral hemorrhage in 2 patients. Perform complete blood cell counts at baseline and during treatment as clinically indicated. Consider withholding and/or reducing the dose based on severity.


Infusion-Related Reactions: Infusion-related reactions occurred in 18% of 218 patients in the pooled safety population, including Grade 3 in 1.8%. Monitor patients for infusion-related reactions. For Grade 2 or 3 reactions, interrupt the infusion and provide supportive treatment. Once symptoms resolve, resume at a lower infusion rate. Administer premedication for all subsequent infusions. Discontinue BLENREP for life-threatening infusion-related reactions and provide appropriate emergency care.


Embryo-Fetal Toxicity: Based on its mechanism of action, BLENREP can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BLENREP and for 4 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BLENREP and for 6 months after the last dose. Pregnancy testing is recommended for females of reproductive potential prior to initiating BLENREP.


ADVERSE REACTIONS

The pooled safety population described in Warnings and Precautions reflects exposure to BLENREP at a dosage of 2.5 mg/kg or 3.4 mg/kg (1.4 times the recommended dose) administered intravenously once every 3 weeks in 218 patients in DREAMM-2. Of these patients, 194 received a liquid formulation (not the approved dosage form) rather than the lyophilized powder.


Patients received BLENREP at the recommended dosage of 2.5 mg/kg administered intravenously once every 3 weeks (n = 95). Permanent discontinuation due to an adverse reaction occurred in 8% of patients who received BLENREP; keratopathy (2.1%) was the most frequent adverse reaction resulting in permanent discontinuation. Dosage interruptions due to an adverse reaction occurred in 54% of patients who received BLENREP. Adverse reactions which required a dosage interruption in >3% of patients included keratopathy (47%), blurred vision (5%), dry eye (3.2%), and pneumonia (3.2%). Dose reductions due to an adverse reaction occurred in 29% of patients. Adverse reactions which required a dose reduction in >3% of patients included keratopathy (23%) and thrombocytopenia (5%).


The most common adverse reactions (≥20%) were keratopathy (71%), decreased visual acuity (53%), nausea (24%), blurred vision (22%), pyrexia (22%), infusion-related reactions (21%), and fatigue (20%). The most common Grade 3 or 4 (≥5%) laboratory abnormalities were lymphocytes decreased (22%), platelets decreased (21%), hemoglobin decreased (18%), neutrophils decreased (9%), creatinine increased (5%), and gamma-glutamyl transferase increased (5%).


Serious adverse reactions occurred in 40% of patients who received BLENREP. Serious adverse reactions in >3% of patients included pneumonia (7%), pyrexia (6%), renal impairment (4.2%), sepsis (4.2%), hypercalcemia (4.2%), and infusion-related reactions (3.2%). Fatal adverse reactions occurred in 3.2% of patients, including sepsis (1%), cardiac arrest (1%), and lung infection (1%).


USE IN SPECIFIC POPULATIONS

Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with BLENREP and for 3 months after the last dose.


Females and Males of Reproductive Potential: Based on findings in animal studies, BLENREP may impair fertility in females and males.


Geriatric Use: Of the 218 patients who received BLENREP in DREAMM-2, 43% were aged 65 to less than 75 years and 17% were aged 75 years and older. Keratopathy occurred in 80% of patients aged less than 65 years and 73% of patients aged 65 years and older. Among the 95 patients who received BLENREP at the 2.5-mg/kg dose, keratopathy occurred in 67% of patients aged less than 65 years and 73% of patients aged 65 years and older.


Renal or Hepatic Impairment: The recommended dosage has not been established in patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2) or end-stage renal disease (ESRD) with eGFR <15 mL/min/1.73 m2 not on dialysis or requiring dialysis. The recommended dosage has not been established in patients with moderate or severe hepatic impairment (total bilirubin >1.5 × ULN and any AST).


Please see full Prescribing Information, including BOXED WARNING.


TEXT ON SCREEN (Scrolling ISI):

IMPORTANT SAFETY INFORMATION (CONT’D)

WARNINGS AND PRECAUTIONS

Ocular Toxicity: Ocular adverse reactions occurred in 77% of the 218 patients in the pooled safety population. Ocular adverse reactions included keratopathy (76%), changes in visual acuity (55%), blurred vision (27%), and dry eye (19%). Among patients with keratopathy (n = 165), 49% had ocular symptoms, 65% had clinically relevant visual acuity changes (decline of 2 or more lines on Snellen Visual Acuity in any eye), and 34% had both ocular symptoms and visual acuity changes.


Keratopathy: Keratopathy was reported as Grade 1 in 7% of patients, Grade 2 in 22%, Grade 3 in 45%, and Grade 4 in 0.5% per the KVA scale. Cases of corneal ulcer (ulcerative and infective keratitis) have been reported. Most keratopathy events developed within the first 2 treatment cycles (cumulative incidence of 65% by Cycle 2). Of the patients with Grade 2 to 4 keratopathy (n = 149), 39% recovered to Grade 1 or lower after median follow-up of 6.2 months. Of the 61% who had ongoing keratopathy, 28% were still on treatment, 9% were in follow-up, and in 24% the follow-up ended due to death, study withdrawal, or lost to follow-up. For patients in whom events resolved, the median time to resolution was 2 months (range: 11 days to 8.3 months).


Visual Acuity Changes: A clinically significant decrease in visual acuity of worse than 20/40 in the better-seeing eye was observed in 19% of the 218 patients and of 20/200 or worse in the better-seeing eye in 1.4%. Of the patients with decreased visual acuity of worse than 20/40, 88% resolved and the median time to resolution was 22 days (range: 7 days to 4.2 months). Of the patients with decreased visual acuity of 20/200 or worse, all resolved and the median duration was 22 days (range: 15 to 22 days).


Monitoring and Patient Instruction: Conduct ophthalmic examinations (visual acuity and slit lamp) at baseline, prior to each dose, and promptly for worsening symptoms. Perform baseline examinations within 3 weeks prior to the first dose. Perform each follow-up examination at least 1 week after the previous dose and within 2 weeks prior to the next dose. Withhold BLENREP until improvement and resume at same or reduced dose, or consider permanently discontinuing based on severity. Advise patients to use preservative-free lubricant eye drops at least 4 times a day starting with the first infusion and continuing until end of treatment. Avoid use of contact lenses unless directed by an ophthalmologist. Changes in visual acuity may be associated with difficulty for driving and reading. Advise patients to use caution when driving or operating machinery. BLENREP is only available through a restricted program under a REMS.


Thrombocytopenia: Thrombocytopenia occurred in 69% of 218 patients in the pooled safety population, including Grade 2 in 13%, Grade 3 in 10%, and Grade 4 in 17%. The median time to onset of the first thrombocytopenic event was 26.5 days. Thrombocytopenia resulted in dose reduction, dose interruption, or discontinuation in 9%, 2.8%, and 0.5% of patients, respectively. Grade 3 to 4 bleeding events occurred in 6% of patients, including Grade 4 in 1 patient. Fatal adverse reactions included cerebral hemorrhage in 2 patients. Perform complete blood cell counts at baseline and during treatment as clinically indicated. Consider withholding and/or reducing the dose based on severity.


Infusion-Related Reactions: Infusion-related reactions occurred in 18% of 218 patients in the pooled safety population, including Grade 3 in 1.8%. Monitor patients for infusion-related reactions. For Grade 2 or 3 reactions, interrupt the infusion and provide supportive treatment. Once symptoms resolve, resume at a lower infusion rate. Administer premedication for all subsequent infusions. Discontinue BLENREP for life-threatening infusion-related reactions and provide appropriate emergency care.


Embryo-Fetal Toxicity: Based on its mechanism of action, BLENREP can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BLENREP and for 4 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BLENREP and for 6 months after the last dose. Pregnancy testing is recommended for females of reproductive potential prior to initiating BLENREP.


ADVERSE REACTIONS

The pooled safety population described in Warnings and Precautions reflects exposure to BLENREP at a dosage of 2.5 mg/kg or 3.4 mg/kg (1.4 times the recommended dose) administered intravenously once every 3 weeks in 218 patients in DREAMM-2. Of these patients, 194 received a liquid formulation (not the approved dosage form) rather than the lyophilized powder.

Patients received BLENREP at the recommended dosage of 2.5 mg/kg administered intravenously once every 3 weeks (n = 95). Permanent discontinuation due to an adverse reaction occurred in 8% of patients who received BLENREP; keratopathy (2.1%) was the most frequent adverse reaction resulting in permanent discontinuation. Dosage interruptions due to an adverse reaction occurred in 54% of patients who received BLENREP. Adverse reactions which required a dosage interruption in >3% of patients included keratopathy (47%), blurred vision (5%), dry eye (3.2%), and pneumonia (3.2%). Dose reductions due to an adverse reaction occurred in 29% of patients. Adverse reactions which required a dose reduction in >3% of patients included keratopathy (23%) and thrombocytopenia (5%).

The most common adverse reactions (≥20%) were keratopathy (71%), decreased visual acuity (53%), nausea (24%), blurred vision (22%), pyrexia (22%), infusion-related reactions (21%), and fatigue (20%). The most common Grade 3 or 4 (≥5%) laboratory abnormalities were lymphocytes decreased (22%), platelets decreased (21%), hemoglobin decreased (18%), neutrophils decreased (9%), creatinine increased (5%), and gamma-glutamyl transferase increased (5%).

Serious adverse reactions occurred in 40% of patients who received BLENREP. Serious adverse reactions in >3% of patients included pneumonia (7%), pyrexia (6%), renal impairment (4.2%), sepsis (4.2%), hypercalcemia (4.2%), and infusion-related reactions (3.2%). Fatal adverse reactions occurred in 3.2% of patients, including sepsis (1%), cardiac arrest (1%), and lung infection (1%).


USE IN SPECIFIC POPULATIONS

Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with BLENREP and for 3 months after the last dose.


Females and Males of Reproductive Potential: Based on findings in animal studies, BLENREP may impair fertility in females and males.


Geriatric Use: Of the 218 patients who received BLENREP in DREAMM-2, 43% were aged 65 to less than 75 years and 17% were aged 75 years and older. Keratopathy occurred in 80% of patients aged less than 65 years and 73% of patients aged 65 years and older. Among the 95 patients who received BLENREP at the 2.5-mg/kg dose, keratopathy occurred in 67% of patients aged less than 65 years and 73% of patients aged 65 years and older.


Renal or Hepatic Impairment: The recommended dosage has not been established in patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2) or end-stage renal disease (ESRD) with eGFR <15 mL/min/1.73 m2 not on dialysis or requiring dialysis. The recommended dosage has not been established in patients with moderate or severe hepatic impairment (total bilirubin >1.5 × ULN and any AST).


Please see full Prescribing Information, including BOXED WARNING.

 


VO: If you have questions, please call us at 1-855-209-9188.
TEXT ON SCREEN: Enroll your patients at
BLENREPHCP.com
Call us at 1-855-209-9188


TEXT ON SCREEN: BLENREP
belantamab mafodotin-blmf
for injection 100 mg


Please see full Prescribing Information, including BOXED WARNING.
Trademarks are owned by or licensed to the GSK group of companies.
©2021 GSK or licensor.
BLMVID210002 August 2021
Produced in USA.


 

Eye drop administration

  • Watch this instructional video with best practices for patients using eye drops.

TEXT ON SCREEN: GSK ONCOLOGY ON DEMAND


VO: Welcome to our video, “The Proper Use of Eye Drops.” To demonstrate the proper way to use eye drops we will show you how to use preservative-free lubricant eye drops.
TEXT ON SCREEN: THE PROPER USE OF EYE DROPS


VO: Preservative-free lubricant eye drops provide moisture to the eye which can help to soothe feelings of dryness.


VO: Step 1: Before Putting In Eye Drops
TEXT ON SCREEN: STEP 1: BEFORE PUTTING IN EYE DROPS


VO: Before opening the vial and putting eye drops in your eyes, remember to wash your hands with soap and water for 20-30 seconds.
TEXT ON SCREEN: WASH HANDS WITH SOAP / 20-30 SECONDS


VO: Next, read the label to confirm that you have the correct eye drop.
TEXT ON SCREEN: READ LABEL

VO: Because labels can vary among different types of eye drops, remember the following: check the expiration date, check the recommended time to discard, and follow the instructions of your healthcare professional as they may vary from the general directions on the package.
TEXT ON SCREEN: CHECK THE EXPIRATION DATE AND RECOMMENDED TIME TO DISCARD


VO: Step 2: How to Put In Eye Drops
TEXT ON SCREEN: STEP 2: HOW TO PUT IN EYE DROPS


VO: To begin, open the vial. Be careful to not touch the tip of the vial to your eye or other objects.
TEXT ON SCREEN: OPEN THE VIAL


VO: Then, while sitting in a chair, lean your head back and tilt your chin up towards the ceiling.
TEXT ON SCREEN: LEAN YOUR HEAD BACK AND TILT YOUR CHIN UP TOWARDS THE CEILING


VO: Next, open both eyes. With your free hand, gently pull down your lower eyelid to create a “pouch” or “pocket,” which helps to catch the eye drop.
TEXT ON SCREEN: GENTLY PULL DOWN YOUR LOWER EYELID TO CREATE A “POUCH” OR “POCKET”


VO: Then, hold the vial as close to your eye as possible. Again, remember to not touch your eye with the tip. If your hand is shaking, rest your hand with the vial either on your face or on your other hand.
TEXT ON SCREEN: HOLD THE VIAL AS CLOSE TO YOUR EYE AS POSSIBLE WITHOUT TOUCHING IT
DO NOT TOUCH YOUR EYE WITH THE TIP


VO: Next, squeeze the belly of the vial until 1 drop falls into your eye. If you do not feel a drop in your eye, add another drop.
TEXT ON SCREEN: SQUEEZE THE BELLY OF THE VIAL UNTIL 1 DROP FALLS INTO YOUR EYE


VO: Slowly let go of your lower eyelid, then gently close both eyes for 30 seconds to 1 minute. Using your finger, apply light pressure to the inner corner of your eyelid, next to your nose, to close the tear ducts. This helps the eye drop to be fully absorbed into the eye.
TEXT ON SCREEN: GENTLY CLOSE BOTH EYES FOR 30 SECONDS TO 1 MINUTE


VO: Carefully blot away excess liquid that may be on your skin.


VO: Next, open both eyes and repeat the above steps with your other eye. Note that your vision may be slightly blurry for a few minutes from the drops.
TEXT ON SCREEN: REPEAT THE SAME PROCEDURE WITH THE OTHER EYE


VO: As an alternative method, you may also lie down on a flat surface like your bed or sofa. With your eyes closed and without touching the bottle to your eyelid, put an eye drop in the corner of your eye near your nose. Then, blink to let the drop enter the eye.


VO: Step 3: After Putting In Eye Drops
TEXT ON SCREEN: STEP 3: AFTER PUTTING IN EYE DROPS


VO: Now that you have put in your eye drops, wash your hands again with soap and water for 20-30 seconds. To properly care for your eye drops, store the box of vials according to the manufacturer’s instructions.
TEXT ON SCREEN: WASH HANDS WITH SOAP / 20-30 SECONDS


VO: As an additional tip, a family member or caregiver can help if you have difficulty putting in your eye drops. Make sure that they wash their hands before providing you with assistance. There are also eye drop assistance devices which come in several forms. These devices can help with squeezing the vial, keeping the eye open, and aiming the eye drop. You can ask your healthcare professional about the right device for you.


VO: Finally, remember to follow the instructions of your healthcare professional when putting in your eye drops.
TEXT ON SCREEN: FOLLOW THE INSTRUCTIONS OF YOUR HEALTHCARE PROFESSIONAL WHEN PUTTING IN YOUR EYE DROPS


TEXT ON SCREEN: THANK YOU FOR WATCHING
Trademarks are property of their respective owners.
©2021 GSK or licensor.
BLMVID210016 August 2021
Produced in USA.

Learn more about management considerations for ocular reactions before and during treatment.

Eye Drop Administration Instructions

RESOURCES*

Eye Care Professional Ocular GuideEye Care Professional Ocular Guide

Eye Care Professional Ocular Guide

An overview of the ocular adverse events associated with BLENREP for the eye care professional partner and their office staff.

HCP Ocular GuideHCP Ocular Guide

HCP Ocular Guide

An overview of the ocular adverse events associated with BLENREP for the prescribing oncologist and their office staff.

Eye Care Professional Quick Reference CardEye Care Professional Quick Reference Card

Eye Care Professional Quick Reference Flashcard

Learn about the eye care professional’s role in the BLENREP treatment journey.

Eye Care Professional Resources FlashcardEye Care Professional Resources Flashcard

Eye Care Professional Resources Flashcard

Information for eye care professionals to support the management of patients on BLENREP treatment.

*See accompanying full Prescribing Information.